FDA Grants Full Approval to Lilly's Inluriyo for ESR1-Mutated Breast Cancer
LLY sits 65% above its 52-week low of $712.05.
Summary
The FDA granted full approval to Inluriyo (imlunestrant) in combination with Verzenio for pretreated ER+/HER2- ESR1-mutated advanced breast cancer. The approval is based on the Phase 3 EMBER-3 trial, where the combination doubled median progression-free survival to 11.1 months versus 5.5 months for Inluriyo alone. This expands Lilly's oncology franchise and leverages the established Verzenio brand. TD Securities projects Inluriyo sales of $290 million in 2026, rising to $1.05 billion by 2032. The adjuvant setting (EMBER-4 trial) represents a larger opportunity, with initial results expected in 2027.
At the time of this announcement, LLY was trading at $1,171.34 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.